Navigation Links
GRAS Status Opens Door to U.S. Food Industry
Date:3/18/2008

MELBOURNE, Australia, March 18 /PRNewswire-FirstCall/ -- Phosphagenics Limited ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced that an independent panel ("the panel") of food safety experts unanimously concluded that Phosphagenics' patented Phospha E(R) is Generally Recognized As Safe (GRAS). This comes as a result of the panel critically evaluating data and information pertinent to the use of Phospha E(R) in breakfast cereals, juice beverages and table fats.

Phospha E(R) is a patented derivative of vitamin E with superior qualities, such as greater absorption and activity. In pre-clinical studies, Phospha E(R), when given orally, has been shown to lower blood cholesterol and triglyceride levels, inhibit the formation of arterial plaques and suppress the main inflammatory pathways involved in metabolic syndrome (a condition which markedly increases the risk of heart attacks, strokes and diabetes).

The Company is preparing a GRAS notification to inform the U.S. Food and Drug Administration ("FDA") of the expert panel's conclusion that Phosphagenics' Phospha E(R) is GRAS. If the FDA has no further comment, GRAS designation allows manufacturers to produce and sell foods that include Phospha E(R) in the U.S. food industry.

"GRAS status extends the permitted use of Phospha E(R) beyond the nutritional supplement market and into the substantial U.S. food industry, and represents a tremendous commercial opportunity for Phosphagenics," said Harry Rosen, Phosphagenics' President and CEO.

APPENDIX AND NOTES TO EDITORS

About GRAS

Generally Recognized as Safe (GRAS) is an FDA designation that a chemical or substance added to food is considered safe by experts, and so is exempted from the usual Federal Food, Drug, and Cosmetic Act (FFDCA) food additive tolerance requirements.

GRAS exemptions are granted for substances that are generally recognized, among experts qualified by scientific training and exper
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
2. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
3. GenoLogics Geneus Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform
4. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
5. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
6. IsoTis Reports Status of Merger Vote
7. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
8. Ganeden Biotech Obtains Self-Affirmed GRAS Status for Probiotic Ingredient, GanedenBC30 (Bacillus coagulans GBI-30, 6086)
9. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
10. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PARK, Calif. , July 24, 2014 ... seven-year contract with the National Institute of Allergy and ... Health, to conduct preclinical development of potential therapies for ... of drugs to treat HIV and AIDS and the ... well as microbicides for preventing sexual transmission of HIV. ...
(Date:7/24/2014)... 24, 2014 Three companies from the ... Livestrong’s Big C Competition. Out of 700 competition entrants, ... to the semi-final round. In this round twenty teams ... program, complete with mentoring from thought-leaders and medical entrepreneurs ... of the angelMD commitment to the Livestrong vision around ...
(Date:7/24/2014)... -- Neogen Corporation (Nasdaq: NEOG ) advised market ... from new rodenticide research are premature. In its regular ... 22, 2014, Neogen,s CEO commented about several new developments ... "It was my intent Tuesday at our conference call ... type of rodenticide, but certainly not to give any ...
(Date:7/24/2014)... July 24, 2014 1000 balances – ... input on customers’ weighing needs and expertly narrows down ... of balances, scales or even terminals. , First, ... smallest weight (or select readability instead) and define the ... additional selection criteria narrows down the list to models ...
Breaking Biology Technology:National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2Neogen comments on SenesTech 2
... CV Therapeutics, Inc. (Nasdaq: CVTX ) today ... and rejected the previously announced unsolicited proposal from Astellas ... of $16.00 per share. After careful consideration of ... the CV Therapeutics board concluded that the Astellas proposal ...
... February 20 Nyenrode Business,Universiteit has awarded a ... the field of microeconomics, competitive strategy and cluster,theory. ... of the modern,field of strategy and the world,s ... and competitive strategy. Professor Porter will receive,the Honorary ...
... Guidance of $0.90 to $1.10 for 2009 and $1.50 to $1.70 ... ) today announced its financial results for the three and twelve ... of $0.90 to $1.10 for 2009 and $1.50 to $1.70 for ... Adjusted diluted EPS of $0.26 ...
Cached Biology Technology:CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 2CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 3CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal 4Nyenrode Honorary Doctorate for Professor Michael E. Porter 2Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 2Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 3Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 4Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 5Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 6Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 7Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 8Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 9Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 10Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 11Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 12Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 13Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 14Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 15Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 16Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008 17
(Date:7/24/2014)... Parts of the primordial soup in which life arose have ... the University of East Anglia. , Research published today in ... in plants, yeast and very likely also in animals still ... origin of life some four billion years ago. , ... pond or ocean as a result of the combination of ...
(Date:7/24/2014)... Africa in mid-July 2014, as the annual fire season ... areas of increased temperatures, are heavily sprinkled across the ... Congo (northeast), and Zambia (southeast). Thick gray smoke rises ... especially in the Democratic Republic of the Congo, strong ... fire season is an annual event in this region, ...
(Date:7/24/2014)... Expanding on his work with a new drug that successfully ... of Houston has received a $250,000 grant to expand his ... effort to treat a wider range of autoimmune diseases., Chandra ... biomedical Engineering at UH, previously published a study in Arthritis ... that successfully treated lupus in mice and reduced the number ...
Breaking Biology News(10 mins):Biomedical engineer looks at new applications for novel lupus drug 2Biomedical engineer looks at new applications for novel lupus drug 3
... group of European experts on biodiversity will gather from the ... to further improve the transfer of biodiversity knowledge from the ... will take part in a project funded by the European ... by researchers and practitioners to help all actors in the ...
... in milk powder and in meat-based baby food, residues ... the University of Almera (Spain) have developed a system ... such as tilmicosine, or antiparasitic drugs, such as levamisole, ... but they can remain later in food. Scientists from ...
... genetic testing that can indicate their range of risk ... appreciably drive up or diminish test recipients, demand for ... performed by researchers at the National Institutes of Health ... the May 17, 2012 early online issue of ...
Cached Biology News:A network of knowledge on biodiversity and ecosystem services in Europe 2A new method detects traces of veterinary drugs in baby food 2NIH-led study finds genetic test results do not trigger increased use of health services 2NIH-led study finds genetic test results do not trigger increased use of health services 3NIH-led study finds genetic test results do not trigger increased use of health services 4
Human VASA Biotinylated Affinity Purified PAb...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
... kit for all types of yeast two-hybrid studies, including ... Choice of two bait vectors for ... Triple reporter strain ... Complete set of controls: pLexA-p53, ...
Mouse Limitin MAb (Clone 183727)...
Biology Products: